298 related articles for article (PubMed ID: 24065147)
1. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.
Niederst MJ; Engelman JA
Sci Signal; 2013 Sep; 6(294):re6. PubMed ID: 24065147
[TBL] [Abstract][Full Text] [Related]
2. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.
Piper AK; Penney C; Holliday J; Tincknell G; Ma Y; Napaki S; Pantel K; Brungs D; Ranson M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791602
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
Hojjat-Farsangi M
Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase inhibitors in cancer.
Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
[TBL] [Abstract][Full Text] [Related]
5. The pharmacogenomics of drug resistance to protein kinase inhibitors.
Gillis NK; McLeod HL
Drug Resist Updat; 2016 Sep; 28():28-42. PubMed ID: 27620953
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors in lung cancer.
Thomas A; Rajan A; Giaccone G
Hematol Oncol Clin North Am; 2012 Jun; 26(3):589-605, viii. PubMed ID: 22520981
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteomic studies of receptor tyrosine kinases: future perspectives.
Huang PH
Mol Biosyst; 2012 Apr; 8(4):1100-7. PubMed ID: 22134727
[TBL] [Abstract][Full Text] [Related]
8. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
Matsumura I; Mizuki M; Kanakura Y
Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
[TBL] [Abstract][Full Text] [Related]
9. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
Bhusare N; Kumar M
Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
[TBL] [Abstract][Full Text] [Related]
10. The neuronal receptor tyrosine kinase Alk is a target for longevity.
Woodling NS; Aleyakpo B; Dyson MC; Minkley LJ; Rajasingam A; Dobson AJ; Leung KHC; Pomposova S; Fuentealba M; Alic N; Partridge L
Aging Cell; 2020 May; 19(5):e13137. PubMed ID: 32291952
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
Kleczko EK; Heasley LE
Mol Cancer; 2018 Feb; 17(1):60. PubMed ID: 29458371
[TBL] [Abstract][Full Text] [Related]
12. Bacterial Phytochrome as a Scaffold for Engineering of Receptor Tyrosine Kinases Controlled with Near-Infrared Light.
Leopold AV; Pletnev S; Verkhusha VV
J Mol Biol; 2020 Jun; 432(13):3749-3760. PubMed ID: 32302608
[TBL] [Abstract][Full Text] [Related]
13. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors.
Wang SC; Hung MC
Clin Cancer Res; 2009 Nov; 15(21):6484-9. PubMed ID: 19861462
[TBL] [Abstract][Full Text] [Related]
14. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors.
Lin NU; Winer EP
Breast Cancer Res; 2004; 6(5):204-10. PubMed ID: 15318926
[TBL] [Abstract][Full Text] [Related]
15. Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?
Aveic S; Tonini GP
Cancer Cell Int; 2016; 16():62. PubMed ID: 27486382
[TBL] [Abstract][Full Text] [Related]
16. Genetic code expansion, click chemistry, and light-activated PI3K reveal details of membrane protein trafficking downstream of receptor tyrosine kinases.
Koh DS; Stratiievska A; Jana S; Otto SC; Swanson TM; Nhim A; Carlson S; Raza M; Naves LA; Senning EN; Mehl RA; Gordon SE
bioRxiv; 2024 Jun; ():. PubMed ID: 37693391
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinase coactivation networks in cancer.
Xu AM; Huang PH
Cancer Res; 2010 May; 70(10):3857-60. PubMed ID: 20406984
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Crystal AS; Shaw AT; Sequist LV; Friboulet L; Niederst MJ; Lockerman EL; Frias RL; Gainor JF; Amzallag A; Greninger P; Lee D; Kalsy A; Gomez-Caraballo M; Elamine L; Howe E; Hur W; Lifshits E; Robinson HE; Katayama R; Faber AC; Awad MM; Ramaswamy S; Mino-Kenudson M; Iafrate AJ; Benes CH; Engelman JA
Science; 2014 Dec; 346(6216):1480-6. PubMed ID: 25394791
[TBL] [Abstract][Full Text] [Related]
19. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.
Arteaga CL; Engelman JA
Cancer Cell; 2014 Mar; 25(3):282-303. PubMed ID: 24651011
[TBL] [Abstract][Full Text] [Related]
20. Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT; Kim DW; Mehra R; Tan DS; Felip E; Chow LQ; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Lau YY; Goldwasser M; Boral AL; Engelman JA
N Engl J Med; 2014 Mar; 370(13):1189-97. PubMed ID: 24670165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
